Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP- malignant cells: Restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis

Molecular Pharmacology

Volumn 52, Issue 5, 1997, Pages 903-911

  Chen, Zhi Hao ^a   Olopade, Olufunmilayo I ^b   Savarese, Todd M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; ADENINE NUCLEOTIDE; AZASERINE; COMPLEMENTARY DNA; FOLIC ACID ANTAGONIST; METHIONINE; METHOTREXATE; POLYAMINE; PROTEIN P16; PURINE;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CHROMOSOME 9P; CONTROLLED STUDY; DNA TRANSFECTION; DRUG MECHANISM; DRUG SENSITIVITY; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; PANCREAS CARCINOMA; PRIORITY JOURNAL; PURINE SYNTHESIS; TUMOR SUPPRESSOR GENE;

EID: 0030864215     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.52.5.903     Document Type: Article

References (38)

1. Schlenk, F., Methylthioadenosine, in Advances in Enzymology and Related Areas in Molecular Biology (A. Meister, ed). John Wiley, New York, 195-265 (1983).
2. Savarese, T. M., G. W. Crabtree, and R. E. Parks, Jr. Methylthioadenosine phosphorylase. I: substrate activity of 5′-deoxyadenosine with the enzyme from Sarcoma 180 cells. Biochem. Pharmacol. 30:189-199 (1981).
3. Backlund, P. S., Jr., and R. A. Smith. Methionine synthesis from 5′-methylthioadenosine in rat liver. J. Biol. Chem. 256:1533-1535 (1981).
4. Trackman, P. C., and R. H. Abeles. Methionine synthesis from 5′-S-methylthioadenosine. J. Biol. Chem. 258:6717-6720 (1983).
5. Williams-Ashman, H. G., J. Seidenfeld, and P. Galletti. Trends in the biochemical pharmacology of 5′-deoxy-5′-methylthioadenosine. Biochem. Pharmacol. 32:277-288 (1982).
6. Kamatani, N., W. A. Nelson-Rees, and D. A. Carson. Selective killing of human malignant cell lines deficient in methylthioadenosine phosphorylase, a purine metabolic enzyme. Proc. Natl. Acad. Sci. USA 78:1219-1223 (1981).
7. INK4, methylthioadenosine phosphorylase, and the α-and β-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. Cancer Res. 56:1083-1090 (1996).
8. Hori H., P. Tran, C. J. Carrera, Y. Hori, M. D. Rosenbach, D. A. Carson, and T. Nobori. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells. Cancer Res. 56:5653-5658 (1996).
9. Backlund, P. S., Jr., and R. A. Smith. 5′-Methylthioadenosine metabolism and methionine synthesis in mammalian cells grown in culture. Biochem. Biophys. Res. Commun. 108:687-694 (1982).
10. Toohey, J. I. Methylthioadenosine nucleoside phosphorylase deficiency in methylthio-dependent cancer cells. Biochem. Biophys. Res. Commun. 83: 27-35 (1978).
11. Kamatani N., A. L. Yu, and D. A. Carson. Deficiency of methylthioadenosine phosphorylase in human leukemic cells in vivo. Blood 60:1387-1391 (1982).
12. Fitchen, J. H., M. K. Riscoe, B. W. Dana, H. J. Lawrence, and A. J. Ferro. Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors. Cancer Res. 46:5409-5412 (1986).
13. Nobori T., J. G. Karras, F. Della Ragione, T. A. Waltz, P. P. Chen, and D. A. Carson. Absence of methylthioadenosine phosphorylase in human gliomas. Cancer Res. 51:3193-3197 (1991).
14. Nobori T., I. Szinai, D. Amox, B. Parker, O. I. Olopade, D. L. Buchhagen, and D. A. Carson. Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers. Cancer Res. 53:1098-1101 (1993).
15. Kamatani, N., and D. A. Carson. Abnormal regulation of methylthioadenosine and polyamine metabolism in methylthioadenosine phosphorylase-deficient human leukemic cell lines. Cancer Res. 40:4178-4182 (1980).
16. Diaz, M. O., S. Ziemin, M. M. LeBeau, P. Pitha, S. D. Smith, R. R. Chilcote, and J. D. Rowley. Homozygous deletion of the α-and β-interferon genes in human leukemia and derived cell lines. Proc. Natl. Acad. Sci. USA 85:5259-5263 (1988).
17. Trent, J. M., S. Olson, and R. M. Lawn. Chromosomal localization of human leukocyte, fibroblast and immune interferon genes by means of in situ hybridization. Proc. Natl. Acad. Sci. USA 79:7809-7813 (1982).
18. Olopade O. I., S. K. Bohlander, H. Pomykala, E. Maltepe, E. V. Melle, M. M. LeBeau, and M. O. Diaz. Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia. Genomics 14:437-443 (1992).
19. Kamb, A., N. A. Gruis, J. Weaver-Fledhaus, Q. Liu, K. Harshman, S. V. Tavtigian, E. Stockert, R. S. Day III, B. E. Johnson, and M. H. Skolnick. A cell cycle regulator potentially involved in the genesis of many tumor types. Science (Washington D. C.) 264:436-440 (1994).
20. Serrano, M., G. J. Hannon, and D. Beach. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.) 366:704-707 (1993).
21. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature (Lond.) 371:257-261 (1994).
22. Pollock, P. M., J. V. Pearson, and N. K. Hayward. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chrom. Cancer 15:77-88 (1996).
23. Olopade, O. I., H. M. Pomykala, F. Hagos, L. W. Sveen, R. Espinosa III, M. H. Dreyling, S. Gursky, W. M. Stadler, M. M. LeBeau, and S. K. Bohlander. Construction of a 2.8 megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc. Natl. Acad. Sci. USA 92:6489-6493 (1995).
24. INK4, methylthio-adenosine phosphorylase, interferon-α1, interferon-β1 and other 9p21 markers in human malignant cell lines. Can. Gen. Cytogenet. 86:22-28 (1996).
25. Riscoe, M. K., and A. J. Ferro. 5-Methylthioribose: its effects and function in mammalian cells. J. Biol. Chem. 259:5465-5471 (1984).
26. Savarese, T. M., S. H. Chu, M. Y. Chu, and R. E. Parks, Jr. 5′-Deoxy-5′-methylthioadenosine phosphorylase. III. Role of the enzyme in the metabolism and action of 5′-halogenated adenosine analogs. Biochem. Pharmacol. 34:361-367 (1985).
27. Gordon, R. B., A. C. Counsilman, S. M. C. Cross, and B. T. Emmerson. Purine synthesis de novo in lymphocytes from patients with gout. Clin. Sci. 63:429-435 (1982).
28. Savarese, T. M., A. J. Cannistra, R. E. Parks, Jr., J. A. Secrist III, A. T. Shortnacy, and J. A. Montgomery. 5′-Deoxy-5′-methylthioadenosine phosphorylase. IV. Biological activity of 2-fluoroadenine-substituted 5′-deoxy-5′-methylthioadenosine analogs. Biochem. Pharmacol. 36:1881-1893 (1987).
29. Henderson, J. F. Substrate concentration and inhibition of purine biosynthesis by end products, in Regulation of Purine Biosynthesis. American Chemical Society, Washington, D. C., 44-195 (1972).
30. Allegra, C. J., K. Hoang, G. C. Yeh, J. C. Drake, and J. Baram. Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. J. Biol. Chem. 262:13520-13526 (1987).
31. Allegra, C. J., J. C. Drake, J. Jolivet, and B. A. Chabner. Inhibition of phosphoribosyl-aminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Natl. Acad. Sci. USA 82:4881-4885 (1985).
32. Takimoto, C. H. New antifolates: pharmacology and clinical applications. Oncologist 1:68-81 (1996).
33. Goker, E., M. Waltham, A. Kheradpour, T. Trippett, M. Mazumdar, Y. Elisseyeff, B. Schnieders, P. Steinherz, C. Tan, E. Berman, and J. R. Bertino. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 mutations. Blood 86:677-684 (1995).
34. Sano, H., M. Kubota, Y. Kasai, H. Hasimoto, T. Shimizu, S. Adachi, and H. Mikawa. Increased methotrexate-induced DNA strand breaks and cytotoxicity following mutational loss of thymidine kinase. Int. J. Cancer 48:92-95 (1991).
35. Scanlon, K. J., A. R. Cashmore, M. Kashani-Sabet, M. Pallai, R. N. Dreyer, B. A. Moroson, and M. Saketos. Inhibition of methionine uptake by methotrexate in mouse leukemia L1210 cells. Cancer Chemother. Pharmacol. 19:21-24 (1987).
36. Batova, A., M. B. Diccianni, T. Nobori, T. Vu, J. Yu, L. Bridgeman, and A. L. Yu. Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy. Blood 88:3083-3090 (1996).
37. Mendelsohn, L. G., C. Shih, R. M. Schultz, and J. F. Worzalla. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol. Invest. New Drugs, in press.
38. Nakagawa, K., N. K. Conrad, J. Q. Cheng, W.-C. Lee, B. E. Johnson, and M. J. Kelley. Characterization of CDKN2 alteration in tumor cell lines of the NCI Drug Screen Panel. Proc. Am. Assoc. Cancer Res. 37:298 (1996).